scispace - formally typeset
P

Pierre Gerlinger

Researcher at French Institute of Health and Medical Research

Publications -  17
Citations -  1297

Pierre Gerlinger is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Gene & Gene expression. The author has an hindex of 14, co-authored 17 publications receiving 1294 citations.

Papers
More filters
Journal ArticleDOI

The M-twist gene of Mus is expressed in subsets of mesodermal cells and is closely related to the Xenopus X-twi and the Drosophila twist genes.

TL;DR: Northern blot analyses and in situ hybridizations reveal that the 1.7-kb murine M-twist m-RNA is present at early stages, starting at 8 days post coitum, and is expressed the most at 9.5 days in the cephalic and branchial mesectoderm.
Journal ArticleDOI

Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice.

TL;DR: In this article, the activation of the activated human Ha-ras oncogene was subjected to the control of the promoter region of the murine whey acidic protein (Wap) gene, which is expressed in mammary epithelial cells in response to lactogenic hormones.
Journal ArticleDOI

Compartmentalization of MHC class II gene expression in transgenic mice

TL;DR: A set of transgenic mouse lines carrying Ek alpha genes with promoter region deletions was created in an attempt to compartmentalize MHC class II gene expression, finding that one transgenic line is essentially devoid of E complex in the thymic cortex.
Journal ArticleDOI

Correcting an immune-response deficiency by creating E alpha gene transgenic mice.

TL;DR: A cloned Ekα gene was introduced into embryos of mice incapable of expressing their endogenous Eα genes and the transcription of Ekα was accurate and tissue-specific in the resulting transgenic lines and, in macrophages, Ekα transcription could be induced by γ-interferon.
Journal ArticleDOI

Tumour prevention and rejection with recombinant vaccinia.

TL;DR: Examining whether live vaccinia virus recombinants expressing TSA in cells of the vaccinated host might better elicit tumour immunity concluded that tumour-bearing animals could be induced to reject their tumours by inoculation of recombinant.